RxDoctor Payments Data

Jose Kareh Cordero, MD

Cardiovascular Disease · San Juan, PRNPI 1588754642

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $8,150 of the $13,097 with a category attached, or 62.2%. 12 manufacturers reported payments, led by Abbott at 44.1% of the total. Reporting peaked in 2022 at $5,736 and has fallen 71.5% since, to $1,633 in 2025.

$13,097in general payments, 2019–2025

Across 138 payments — averaging $94.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$6K
  • Terumo Medical Corporation$5K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$666
  • Johnson & Johnson$529
  • AstraZeneca$415
  • Medtronic$332
  • plus $433 from 6 others

What the payments were for

  • Consulting fees$8,15062%
  • Speaking & faculty fees$2,00015%
  • Travel & lodging$180%
  • Food & beverage$2,85422%
  • Gifts$751%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,097 in reported general payments places this provider in the 85th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$15,682
Medicare patients
36
Services billed
106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor60$34,532
XareltoRivaroxaban23$27,790
FarxigaDapagliflozin Propanediol34$25,285
EliquisApixaban40$25,151
JanumetSitagliptin Phos/Metformin Hcl13$19,122
SynthroidLevothyroxine Sodium113$9,800
ClopidogrelClopidogrel Bisulfate776$7,550
Trijardy XrEmpaglifloz/Linaglip/Metformin11$6,802
Atorvastatin Calcium428$3,529
Ezetimibe197$2,744
Metoprolol Succinate176$2,512
Losartan Potassium254$2,472
Amlodipine Besylate361$2,038
Fenofibrate93$1,643
Hydrochlorothiazide261$1,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta, Farxiga$415$59,81794 claims
Johnson & JohnsonXarelto$529$27,79023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →